A Frontiers case report details upadacitinib clearing atopic dermatitis that emerged in a patient on secukinumab for refractory ankylosing spondylitis. The single-patient report lands as rheumatologists and dermatologists increasingly weigh how to manage paradoxical cutaneous reactions triggered by biologic therapy.

The patient had ankylosing spondylitis that failed to respond to standard treatment. After starting secukinumab, an anti–IL-17A monoclonal antibody used across psoriatic disease and spondyloarthropathies, the patient developed atopic dermatitis. Clinicians then started upadacitinib, an oral Janus kinase inhibitor, and the skin disease resolved, according to the case report.

What does the case report add to clinical practice?

The report addresses a recurring dilemma. Biologics that treat one immune-mediated condition can sometimes trigger or unmask another. Atopic dermatitis linked to IL-17 pathway blockade has surfaced in scattered case reports and pharmacovigilance data, though the precise mechanism remains incompletely mapped.

When the eruption is mild, topical therapy or drug discontinuation often suffices. When the rash persists or the underlying disease still needs suppression, clinicians must pick a replacement that handles both. The Frontiers case argues for upadacitinib in that dual role.

Upadacitinib carries labeled indications in moderate-to-severe atopic dermatitis and in rheumatologic conditions, positioning it as a candidate for patients whose original biologic triggered a dermatologic complication while joint disease persists.

How should dermatologists read the result?

The case report establishes that upadacitinib controlled secukinumab-induced atopic dermatitis in one patient. The publicly available Frontiers indexing does not surface patient demographics, dosing, treatment duration, follow-up interval, or validated severity scores such as EASI or SCORAD. Without those numbers, the report functions as a hypothesis-generating signal rather than a generalizable outcome.

That distinction matters. Case reports can shift practice when they flag rare events, but they rarely substitute for cohort data or randomized evidence. The single-patient design here means dermatologists should treat the finding as a reasonable option in similar patients, not a guideline-grade recommendation. Sequencing, monitoring, and shared decision-making remain the deciding factors on each case.

What questions does the case leave open?

Three details will determine whether the report changes practice. Did the patient's ankylosing spondylitis also respond to upadacitinib, or did clinicians add a separate agent for joint control? How long did the atopic dermatitis remission last after the switch? Did the patient experience infections, laboratory abnormalities, or other adverse events during upadacitinib therapy? The case report does not address these questions in the indexed metadata.

The mechanism behind secukinumab-induced atopic dermatitis also remains open. IL-17 blockade can shift T-cell polarization in ways that, in some patients, support Th2-driven inflammation. Upadacitinib's JAK1 selectivity interrupts that Th2 signaling, which may explain the response seen in the Frontiers case.

Rheumatologists and dermatologists managing overlapping caseloads will recognize the trade-offs. Stopping secukinumab risks losing control of ankylosing spondylitis. Adding upadacitinib on top increases infection risk and laboratory monitoring burden. Switching outright, as this case did, requires confidence that the replacement handles both indications.

What to watch next

Expect more single-case and small-series reports on Janus kinase inhibitors used to manage biologic-induced skin disease, especially as upadacitinib and related agents expand across dermatology and rheumatology. Pooled analyses, registry data, and post-marketing surveillance will determine whether the dual-action pattern holds across larger patient cohorts.

Dermatologists should also track the parallel story in rheumatology, where JAK inhibitors already compete with IL-17 and TNF blockers across spondyloarthropathies. If upadacitinib continues to show control of both joint disease and biologic-induced skin reactions, rheumatologists and dermatologists may find themselves co-managing more patients on the same drug.

For now, the Frontiers report gives clinicians a documented precedent: a refractory ankylosing spondylitis patient, a secukinumab-induced atopic dermatitis flare, and a switch to upadacitinib that cleared the skin. The durability of that response, and whether other JAK inhibitors reproduce it, will be the next questions on the desk.